SECOND OPINION: PFIZER’S PHONY CALL FOR LOWER DRUG COSTS

06-22-2021 Blog Posts

CEO Sidesteps Big Pharma’s Pricing Practices; Pushes Proposals That Would Boost Drug Company Profits and Incentivize Price Hikes During a recent interview on Bloomberg’s “Balance of Power,” Pfizer CEO Albert Bourla claimed the pharmaceutical industry is willing to be a helpful partner in reducing “significantly the cost of medicines.” What Bourla did not mention in […]

CSRXP: WYDEN RX PRICING PRINCIPLES ADD TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE

06-22-2021 Blog Posts

Lawmakers Must Advance Solutions to Lower Drug Prices  For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday on the release of drug pricing principles from U.S. Senate Committee on Finance Chairman Ron Wyden (D-OR). “CSRxP commends Chairman Wyden for his leadership and dedication to […]

WHAT THEY ARE SAYING: BIOGEN’S “SIMPLY UNACCEPTABLE” ADUCANUMAB PRICING HIGHLIGHTS URGENCY FOR RX SOLUTIONS

06-14-2021 Blog Posts

Broad-based Opposition to Egregious Launch Price on Drug With Unproven Clinical Benefit Adds to Momentum to Hold Big Pharma Accountable Last week, the U.S. Food and Drug Administration (FDA) approved Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and a unanimous vote against moving forward from the […]

ICYMI: BIG PHARMA’S FASTER-THAN-INFLATION PRICE HIKES COSTING MEDICARE BILLIONS OF DOLLARS

06-7-2021 Blog Posts

AARP Study Finds Brand Name Drug Companies Increased Prices Above Rate of Inflation on 90 Percent of Best-Selling Part D Medications In case you missed it, AARP released a new report Monday detailing how drug price increases that exceed the rate of inflation are costing the Medicare Part D program billions of dollars in additional […]

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC

06-7-2021 Blog Posts

For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs. These tired arguments, which Big Pharma wields like a shield to protect the industry’s anti-competitive and price-hiking practices, simply don’t hold up to […]

THEY SAID IT! ABBVIE CEO BRAGS ON ABILITY TO HIKE PRICES IN U.S., ADMITS COMPETITION WORKS AND CONFIRMS BIG PHARMA PATENT GAMES DESIGNED FOR “PRICING POWER”

05-19-2021 Blog Posts

House Oversight Lawmakers Commit to Bipartisan Action to Hold Big Pharma Accountable During Explosive Hearing on Out-of-Control Drug Prices During a hearing Tuesday before the U.S. House Committee on Oversight and Reform, the CEO of AbbVie, the manufacturer of the world’s best-selling drug Humira, was put squarely on the hot seat as lawmakers drilled down […]

DOSE OF REALITY: HUMIRA: A CASE STUDY IN BIG PHARMA GREED

05-17-2021 Blog Posts

AbbVie CEO Headed for Capitol Hill to Answer for Indefensible Anti-Competitive  & Price-Hiking Tactics on World’s Best-Selling Drug On Tuesday, lawmakers in the U.S. House Committee on Oversight and Reform are set to question AbbVie CEO Richard Gonzalez on the Big Pharma company’s pricing and marketing tactics around blockbuster rheumatoid arthritis drug Humira. Humira has […]

THEY SAID IT! LAWMAKERS CALL FOR BIPARTISAN ACTION TO LOWER RX PRICES IN PAIR OF HOUSE HEARINGS

05-5-2021 Blog Posts

Members of Congress in Both Parties Recognize Urgency for Solutions to Deliver Relief for American Patients During a pair of hearings this week in the U.S. House Energy & Commerce Committee Subcommittee on Health and House Education & Labor Committee Subcommittee on Health, Employment, Labor, and Pensions, lawmakers from both parties emphasized the urgent need […]

BIG PHARMA EARNINGS WATCH: PFIZER, ABBVIE & ASTRAZENECA

05-5-2021 Blog Posts

Drug Companies Top Wall Street Expectations; Pfizer Raises Guidance Based On Massive Taxpayer-Funded Vaccine Profits New first quarter earnings reports from Big Pharma giants Pfizer, AbbVie and AstraZeneca topped Wall Street analysts’ expectations. Pfizer, in particular, smashed forecasts and raised its profit guidance for the year. The company’s big time earnings were driven, in large […]

BIG PHARMA EARNINGS WATCH: SANOFI, MERCK, BRISTOL-MYERS SQUIBB, AMGEN & GLAXOSMITHKLINE

05-4-2021 Blog Posts

Brand Name Drug Makers Boosting Profits, Sales After Engaging In Pandemic Price Hikes Another round of first quarter earnings reports from brand name drug makers Sanofi, Merck, Bristol-Myers Squibb (BMS), Amgen, and GlaxoSmithKline (GSK) showcase how Big Pharma continues to bank expectation-beating profits and rising sales against a backdrop of continued price hikes — even […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.